文献速递骨质疏松与代谢性骨病

首次输注唑来膦酸后发生肾上腺危象:一例病例报告

Adrenal crisis after first infusion of zoledronic acid: a case report.
PubMed 文献 · Osteoporos Int · 2018-03-28

一例80岁女性艾迪生病患者因骨质疏松在门诊首次输注唑来膦酸,尽管将下午氢化可的松剂量加倍,仍在夜间出现发热、恶心、极度乏力及低血压,次日被送入ICU并确诊为肾上腺危象,经静脉氢化可的松治疗后迅速好转。作者根据此经验提出,艾迪生病患者或许应在医院环境下开始唑来膦酸治疗,并将常规口服氢化可的松剂量加倍或甚至加至三倍,同时需密切监测,一旦出现肾上腺危象征兆即应静脉给予氢化可的松。

要点

  • 艾迪生病患者接受唑来膦酸输注后可能发生急性期反应并诱发肾上腺危象。
  • 作者认为此类患者或许应在医院环境下开始唑来膦酸治疗。
  • 作者建议将常规口服氢化可的松剂量加倍或甚至加至三倍,并密切监测。

核心结论

  • 作者的经验或许提示,艾迪生病患者可能应在医院环境下开始唑来膦酸治疗,其常规口服氢化可的松剂量应加倍或甚至加至三倍,且似有必要对这些患者进行仔细监测。

研究设计与样本

  • 单例病例报告:一例80岁女性艾迪生病患者因骨质疏松在本中心门诊于中午前后接受首次唑来膦酸输注。

主要发现

  • 该患者尽管将常规下午氢化可的松剂量加倍,仍在夜间出现发热、恶心、极度乏力和低血压。
  • 次日晨被送至最近的综合医院时发现低血容量休克征象并收入ICU,晶体液输注及后续多巴酚丁胺和去甲肾上腺素滴注均无效。
  • 在发现其欧洲糖皮质激素应急卡后识别出肾上腺危象,立即静脉推注氢化可的松并继以持续氢化可的松输注,患者迅速好转,次日转入普通病房并逐渐减量氢化可的松。

关键数值与推荐

  • 作者认为艾迪生病患者或许应在医院环境下开始唑来膦酸治疗。
  • 作者认为其常规口服氢化可的松剂量应加倍或甚至加至三倍。
  • 作者认为似有必要对这些患者进行仔细监测,若注意到任何即将发生肾上腺危象的症状或体征应静脉给予氢化可的松。

临床怎么用

  • 作者根据本病例经验提出,艾迪生病患者或许应在医院环境下开始唑来膦酸治疗。
  • 作者建议此类患者常规口服氢化可的松剂量应加倍或甚至加至三倍。
  • 作者建议对此类患者进行仔细监测,若出现即将发生肾上腺危象的症状或体征应静脉给予氢化可的松。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with Addison's disease are at greater risk of having reduced bone mineral density and hip fractures and are thus more likely to receive a bisphosphonate than their peers. Potent intravenous bisphosphonates could provoke an acute phase reaction. An 80-year-old female with Addison's disease received her first infusion of zoledronic acid for osteoporosis at our outpatient clinic around noon. Despite doubling her usual afternoon hydrocortisone dose, she became feverish, nauseous, extremely weak, and hypotensive over the night. When transported to the nearest general hospital the next morning, the patient was found to have signs of hypovolemic shock and she was admitted to the ICU. Crystalloid infusion, followed by dobutamine and norepinephrine drip, had no effect. Only after her European emergency card for glucocorticoid cover was found, adrenal crisis was recognized, and she was immediately given an intravenous bolus of hydrocortisone followed by continuous hydrocortisone infusion. The patient rapidly improved and was transferred to a regular ward the next day, where hydrocortisone dose was gradually tapered. Our experience might suggest that patients with Addison's disease should probably start their treatment with zoledronic acid in a hospital setting. Their usual oral dose of hydrocortisone should be doubled or even tripled. Careful monitoring of these patients seems to be warranted, and intravenous hydrocortisone should be given if any symptoms or signs of the imminent adrenal crisis are noted.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Smrecnik M, Kavcic Trsinar Z, Kocjan T, et al. Adrenal crisis after first infusion of zoledronic acid: a case report. Osteoporos Int. 2018. PMID: 29594318. doi:10.1007/s00198-018-4508-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。